reports
- Research Department
IBERIAN DAILY 09 JANUARY (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IBERDROLA, SACYR, UNICAJA. Slight losses with the market still affected by rising yields and awaiting employment data European stock markets, which opened with slight gains, ended up doing a 180 after Wall Street opened, awaiting tomorrow’s US employment data and with all eyes on debt yields. The first few days of the year continue to be shaky: the debate continues on at what point, with demanding stock market levels, high interest rates but a still-favourable macro backdrop, ther...
- Research Department
INFORME DIARIO 09 ENERO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, SACYR, UNICAJA. EUROPA: SANOFI. Ligeros retrocesos en bolsa por la subida de la TIR Las bolsas europeas, que abrieron con ligeras subidas, se acabaron dando la vuelta tras la apertura de Wall Street a la espera de la publicación de los datos de empleo americanos mañana y con la mirada puesta en la rentabilidad de la deuda. Se mantiene la indefinición en estos primeros compases del año y prosigue el debate sobre los niveles de valoración ...
Press Release: New Sarclisa subcutaneous formulation met co-primary en...
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDSOBDS is an alternative delivery method designed to improve the patient...
Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclis...
Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclisa a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA dans le myélome multiple La nouvelle formulation sous-cutanée du Sarclisa a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA dans le myélome multiple Le Sarclisa en formulation sous-cutanée et en association avec le schéma Pd pour le traitement du myélome multiple réfractaire ou en rechute a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA et démontré sa non-infériorité au ...
- Javier Esteban
INFORME SECTORIAL BANCOS EUROPA: POCO MOMENTUM SECTORIAL HASTA RDOS. 4...
Poco momentum hasta que publiquen guidance 2025 en Rdos. 4T’24. A la espera del guidance’25 en Rdos. 4T’24 reina la cautela y un apetito limitado por el sector a la espera de que se descarten escenarios muy negativos, en nuestra opinión injustificados. Nosotros esperamos una caída media de ingresos de -3,3% en 2025 (vs -1% consenso) y -10% en BDI (vs -3% consenso) para un EURIBOR de 2,18%. Creemos que queda valor en un sector holgado de capital (13,3% CET1 medio) con una yield por dividendo de ~...
- Research Department
IBERIAN DAILY 08 JANUARY (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: BANKING SECTOR. Rising debt yields once again pressure stock markets European stock markets rose early in the session but ended up reeling in part of those initial gains after a bearish opening for US markets. The main driver was the rising sovereign debt yields following the release of better US macro data and in view of investors selling bond to make room for the US treasury’s 10Y bond auction. In the STOXX 600, the best-performing sectors were once again Energy and those linked...
- Research Department
INFORME DIARIO 08 ENERO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: SECTOR BANCOS. La escalada de la rentabilidad de la deuda vuelve a presionar las bolsas Las bolsas europeas, que subían por la mañana, acabaron cediendo parte de sus ganancias al cierre tras una apertura bajista del mercado americano. El principal catalizador fue la escalada en la rentabilidad de la deuda soberana a largo plazo, tras la publicación de unos mejores datos macro en EE.UU. y ante las ventas de bonos por parte de los inversores para ha...
Iberdrola S.A.: 1 director
A director at Iberdrola S.A. bought 2,000 shares at 13.100EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Press Release: Sanofi initiates phase 3 program for PCV21 and expands ...
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December ...
Communiqué de presse : Sanofi lance un programme de phase III pour son...
Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques conjugués Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques conjugués Les infections à pneumocoques demeurent un enjeu majeur de santé publique malgré les vaccins actuellement disponibles. Ce vaccin pneumococcique conjugué 21-valent (VPC21) est le premier candidat-...
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will hold his position for the remainder of Gilles Schnepp's term of office and his appointment will be subject to ratification at the next Ordinary Shareholders' Meeting of Sanofi. Jean-Paul Kress, M.D., served as the CEO of MorphoS...
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administra...
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024. Le Conseil d’administration de Sanofi est heureux d’accueillir Jean-Paul Kress en qualité d’administrateur indépendant à compter du 1er janvier 2025, en remplacement de Gilles Schnepp qui a décidé de quitter le conseil à la fin de l’année 2024. Jean-Paul Kress exercera ses fonctions pour la durée restant à courir du mandat de Gilles Schnepp et sa nomination sera soumise à la ratification de la prochaine Assemblée Géné...
- Emna Ben Bdira
- Maxime Kogge
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
SAN SANOFI
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
- Emna Ben Bdira
- Maxime Kogge
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
SAN SANOFI
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
Press Release: Duvakitug positive phase 2b results demonstrate best-in...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram under...
Communiqué de presse : Les résultats positifs de phase IIb concernant ...
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les critères d’évaluation primaires ont été satisfaits pour la colite ulcéreuse et la maladie de Crohn, les deux formes les plus courantes de maladies inflammatoires de l’intestin (MII) .Le...
Press Release: Availability of the Q4 2024 Aide-mémoire
Press Release: Availability of the Q4 2024 Aide-mémoire Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024. Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fourth quarter & full year 2024 results will be published on January ...
- Research Department
IBERIAN DAILY 13 DECEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CHANGES IBEX, IBERDROLA. The ECB follows the script The most-awaited event of the week did not bring any surprises, and the ECB cut rates by -25bps to 3.05% (despite the discussion about the possibility of cutting 50bps). C. Lagarde was in favour of further rate cuts to neutral levels (near 2.05%), not making any reference in her communiqué on maintaining a restrictive monetary policy, cutting 2024/25 growth forecasts to 0.7% and 1.1%, respectively and inflation to 2.4% and 2.1%....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.